Janssen Pharmaceutica Nv

Johnson & Johnson Pharmaceutical Research & Development, LLC

Jannsen Pharmaceutica Bv

Mark Seierstad

J Guy Breitenbucher

Wei Xiao

Richard Apodaca

Wenying Chai

John M Keith

Mark S Tichenor

Natalie Anne Hawryluk

Alison L Chambers

Kanaka Pattabiraman

William Moore Jones

Jeffrey E Merit

Aihua Wang

Jennifer Diane Venable

Kevin Douglas Kreutter

Nicholas I Carruthers

Kristi A Leonard

Dale A Rudolph

Paul J Krawczuk

Genesis M Bacani

Jill A Jablonowski

Michele C Rizzolio

Russell C Smith

Tatiana Koudriakova

Amy K Timmons

Scott L Dax

Curt A Dvorak

William V Murray

Neelakandha S Mani

Mark Andrew Youngman

Chandravadan R Shah

Timothy W Lovenberg

Devin M Swanson

Xiaohu Deng

Xiaobing Li

Victoria Wong

Pascal Bonaventure

Joan M Pierce

Kristi Leonard

Russel C Smith

Jennifer D Venable

Kevin D Kreutter

2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.

Imidazopyrrolopyridine as inhibitors of the JAK family of kinases

Certain piperazinyl and piperidinyl urea compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).

Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase

Certain ethylene diamine compounds of Formula (I) are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed. 

Ethylene diamine modulators of fatty acid hydrolase

Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.

Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase

Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).

Heteroaryl-substituted urea modulators of fatty acid amide hydrolase

The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; sleep/wake disorders; cardiovascular disease; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility. The compounds of the present invention are of the formula where Ring T is a heterocycloalkyl ring selected from the group consisting of: 

Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor

Certain N-heteroarylpiperazinyl urea compounds of Formula (I), as defined in the specification, are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis). 

N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase

The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.

Non-peptidic NPY Y2 receptor inhibitors

Growing community of inventors

Escondido, CA, United States of America

Mark Seierstad